| Literature DB >> 28414079 |
Ryan M Pearson1, Liam M Casey2, Kevin R Hughes1, Stephen D Miller3, Lonnie D Shea4.
Abstract
Technologies that induce antigen-specific immune tolerance by mimicking naturally occurring mechanisms have the potential to revolutionize the treatment of many immune-mediated pathologies such as autoimmunity, allograft rejection, and allergy. The immune system intrinsically has central and peripheral tolerance pathways for eliminating or modulating antigen-specific responses, which are being exploited through emerging technologies. Antigen-specific tolerogenic responses have been achieved through the functional reprogramming of antigen-presenting cells or lymphocytes. Alternatively, immune privileged sites have been mimicked using biomaterial scaffolds to locally suppress immune responses and promote long-term allograft survival. This review describes natural mechanisms of peripheral tolerance induction and the various technologies being developed to achieve antigen-specific immune tolerance in vivo. As currently approved therapies are non-specific and carry significant associated risks, these therapies offer significant progress towards replacing systemic immune suppression with antigen-specific therapies to curb aberrant immune responses.Entities:
Keywords: Allergy; Autoimmune disease; Drug delivery; Immune tolerance; Nanoparticle; Regulatory T cells; Transplantation
Mesh:
Substances:
Year: 2017 PMID: 28414079 PMCID: PMC5582017 DOI: 10.1016/j.addr.2017.04.005
Source DB: PubMed Journal: Adv Drug Deliv Rev ISSN: 0169-409X Impact factor: 15.470